The synthesis of a novel series of 5-[(X-benzoylamino)]-1-(2,4-dinitrophenyl)-1H-4-pyrazolecarboxamide derivatives is described. Their antibacterial activity (MIC) against methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MRSA) were determined. The results revealed that two of the compounds, X = 4-MeO and X = 4-NO2, displayed greater antibacterial activity against MRSA than did cephalexin, cloxacillin and erythromycin.
